Antiarrhythmic properties of MJ 9067 in acute animal models.
A novel benzanilide derivative, MJ 9067, has been shown to abolish experimental atrial and ventricular arrhythmiase effectively and promote the return of normal sinus rhythm in a variety of animal models. At intravenous dose levels ranging from 0.5 to 3.2 mg/kg, MJ 9067 successfully converted atrial fibrillation induced by either local application of aconitine or electrical stimulation, and ventricular tachycardia elicited by intravenous injection of ouabain or digoxin. The compound was equally effective in vagotomized or nonvagotomized dogs, and in intact cats and monkeys. The ventricular ectopic rate in conscious dogs 18 to 20 hours after two-stage ligation of a coronary artery was also markedly reduced by the drug at 2 mg/kg i.v. At antiarrhythmic dose levels, there were no undesirable effects noted on peripheral blood pressure, heart rate or the configuration of the electrocardiogram.
D000157:Aconitine / Q000494:pharmacology; D000813:Anilides / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy / Q000209:etiology / Q000503:physiopathology; D001281:Atrial Fibrillation / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology; D001794:Blood Pressure / Q000187:drug effects; D002415:Cats; D004077:Digoxin / Q000494:pharmacology; D004285:Dogs; D004558:Electric Stimulation; D004562:Electrocardiography; D005260:Female; D000882:Haplorhini; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D010042:Ouabain / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology* / Q000627:therapeutic use; D012453:Saimiri; D013610:Tachycardia / Q000139:chemically induced / Q000188:drug therapy / Q000503:physiopathology
D000813:Anilides; D000889:Anti-Arrhythmia Agents; D010880:Piperidines; D010042:Ouabain; D004077:Digoxin; D000157:Aconitine